XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2018
 
2017
Revenue from services:
 
 
 
Pharmaceutical
$
—

 
$
—

Diagnostics
211,315

 
228,545

Corporate
—

 
—

 
$
211,315

 
$
228,545

Revenue from products:
 
 
 
Pharmaceutical
$
27,851

 
$
22,231

Diagnostics
—

 
—

Corporate
—

 
—

 
$
27,851

 
$
22,231

Revenue from transfer of intellectual property and other:
 
 
 
Pharmaceutical
$
15,748

 
$
15,606

Diagnostics
—

 
—

Corporate
—

 
—

 
$
15,748

 
$
15,606

Operating loss:
 
 
 
Pharmaceutical
$
(22,948
)
 
$
(26,145
)
Diagnostics
(8,018
)
 
(3,100
)
Corporate
(11,645
)
 
(15,970
)
 
$
(42,611
)
 
$
(45,215
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
6,740

 
$
6,775

Diagnostics
17,987

 
18,925

Corporate
30

 
30

 
$
24,757

 
$
25,730

Loss from investment in investees:
 
 
 
Pharmaceutical
$
(2,172
)
 
$
(1,814
)
Diagnostics
(284
)
 
(317
)
Corporate
—

 
—

 
$
(2,456
)
 
$
(2,131
)
Revenues:
 
 
 
United States
$
215,311

 
$
229,436

Ireland
17,282

 
17,209

Chile
11,733

 
10,121

Spain
5,532

 
4,505

Israel
3,614

 
4,217

Mexico
1,420

 
865

Other
22

 
29

 
$
254,914

 
$
266,382


(In thousands)
March 31,
2018
 
December 31,
2017
Assets:
 
 
 
Pharmaceutical
$
1,294,067

 
$
1,287,964

Diagnostics
1,226,077

 
1,241,388

Corporate
58,750

 
60,604

 
$
2,578,894

 
$
2,589,956

Goodwill:

 

Pharmaceutical
$
267,104

 
$
264,313

Diagnostics
452,787

 
452,786

Corporate
—

 
—

 
$
719,891

 
$
717,099